Abbreviations {#nomen0010}
=============

BMS

:   bare metal stents

BP-DES

:   biodegradable polymer drug-eluting stents

DAPT

:   dual antiplatelet therapy

DP-DES

:   durable polymer drug-eluting stents

M-H

:   Mantel-Haenszel

MI

:   myocardial infarction

OR

:   odds ratio

PCI

:   percutaneous coronary intervention

PF-DES

:   polymer-free drug-eluting stents

PF-PES

:   polymer-free paclitaxel-eluting stents

RCT

:   randomized controlled trial

RR

:   risk ratio

ST

:   stent thrombosis

TLR

:   target lesion revascularization

TVR

:   target vessel revascularization

1. Introduction {#sec1}
===============

Drug-eluting stents have been a major advance in percutaneous coronary intervention (PCI). New developments in coronary stent technology have contributed to improved outcomes of patients with coronary artery disease. The sequential generations of devices have represented significant milestones in stent design, structure, and component materials \[[@bib1]\]. These stent platforms have included bare metal stents (BMS), durable polymer drug-eluting stents (DP-DES) and polymer-free drug-eluting stents (PF-DES). First-generation DP-DES were developed to reduce the risk of in-stent restenosis and target lesion revascularization associated with BMS \[[@bib2]\]. Despite these promising results, first-generation DP-DES were shown to have an increased risk of very late (\>12 months) stent thrombosis compared with BMS \[[@bib3]\]. The pathophysiology of stent thrombosis has been attributed to various factors, such as polymer-induced hypersensitivity reaction, stent malapposition, incomplete strut re-endothelialization, and accelerated neoatherosclerosis \[[@bib4]\]. To address this issue, a new generation of DP-DES were developed, with improvements in anti-proliferative drugs, polymer coatings, and strut thickness \[[@bib5]\]. The introduction of second-generation DP-DES reduced the risk of very late stent thrombosis associated with the preceding generation of devices \[[@bib6]\]. Nevertheless, the potential thrombogenic nature of the polymer coating in second-generation DP-DES remains a concern, and suggestions have been made to extend the duration of dual antiplatelet therapy (DAPT) in patients receiving DP-DES \[[@bib7]\].

PF-DES were designed to achieve similar advantages of BMS (reduced risk of stent thrombosis) and DP-DES (reduced risk of target lesion revascularization). These devices consist of a microporous metallic stent platform and an inorganic coating that can be loaded with an anti-proliferative drug \[[@bib8]\]. The theoretical benefit of PF-DES is the elimination of the need for a polymer coating, which acts as a potential chronic inflammatory stimulus \[[@bib9]\]. However, the main challenge for PF-DES has been the attainment of a sufficient level of anti-proliferative drug in the inorganic coating to ensure the inhibition of neointimal hyperplasia and in-stent restenosis \[[@bib10]\]. Therefore, we performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the safety and efficacy profiles of PF-DES compared with DP-DES.

2. Methods {#sec2}
==========

2.1. Selection criteria {#sec2.1}
-----------------------

In the present meta-analysis, we included RCTs comparing patients with coronary artery disease who were randomized to receive PCI with either PF-DES or DP-DES. We included studies that assessed at least one of the following clinical outcomes: definite or probable stent thrombosis (ST), myocardial infarction (MI), cardiac death, all-cause death, target lesion revascularization (TLR), and target vessel revascularization (TVR). Only the most recent report with the greatest length of follow-up was included when institutions published progressive reports of an ongoing study. Studies that evaluated other types of stents, such as BMS, biodegradable polymer drug-eluting stents (BP-DES), or bioresorbable vascular scaffolds were excluded. Furthermore, studies that only assessed angiographic outcomes were excluded. Electronic database searches were limited to studies that involved human subjects. Conference abstracts, editorials, case reports, and review articles were excluded.

2.2. Search strategy {#sec2.2}
--------------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to perform the present meta-analysis \[[@bib11]\]. Ovid Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), American College of Physicians (ACP) Journal Club, and Database of Abstracts of Reviews of Effectiveness (DARE) were searched from their dates of inception to October 2018. We identified potentially relevant studies in the electronic database searches using the following keywords or MeSH terms: "randomized controlled trial", "drug-eluting stent", "polymer-free", "durable polymer", "permanent polymer", "sirolimus-eluting stent", "paclitaxel-eluting stent", "everolimus-eluting stent", "zotarolimus-eluting stent", and "stent thrombosis". Reference lists of retrieved articles were screened and assessed according to the inclusion and exclusion criteria.

2.3. Data extraction {#sec2.3}
--------------------

We extracted data from texts, tables, figures, and supplementary materials. There were two investigators (JJW and JAW), who independently screened each retrieved article to determine the suitability for inclusion at the title or abstract level. Studies that met the inclusion and exclusion criteria were included for quantitative assessment. Discussion and consensus with the senior author (DB) occurred when there were discrepancies between the two reviewers. We extracted data for the following baseline characteristics: age, sex, diabetes mellitus, hypertension, hyperlipidemia, current smoking, previous MI, previous procedure (PCI and coronary artery bypass grafting), clinical presentation (stable and unstable angina), and target vessel location (left anterior descending, left circumflex, and right coronary artery). The main outcome of interest was definite or probable ST, as defined by the Academic Research Consortium (ARC) \[[@bib12]\]. We also extracted data for other clinical outcomes, including MI, cardiac death, all-cause death, TLR, and TVR. All outcomes were assessed at the longest follow-up available.

2.4. Critical appraisal and statistical analysis {#sec2.4}
------------------------------------------------

The included studies were qualitatively assessed using the risk of bias tool, which was proposed by the Cochrane Collaboration \[[@bib13]\]. In addition, the risk of publication bias was evaluated by visually estimating funnel plots \[[@bib14]\]. Summary statistics and risk estimates were expressed as risk ratios (RRs) with 95% confidence intervals (CIs) for the comparison of patients receiving PF-DES versus DP-DES. Heterogeneity between studies was evaluated using the χ^2^ test. The percentage of total variation across studies was estimated using the I^2^ statistic, with values greater than 50% indicating significant heterogeneity \[[@bib15]\]. We used the Mantel-Haenszel (M-H) random-effects model because there were assumed variations in treatment effect between studies. Late safety and efficacy outcomes were assessed using a landmark analysis beyond 1 year of follow-up. We also performed subgroup analyses based on the following variables: PF-DES anti-proliferative drug (amphilimus, biolimus, paclitaxel, sirolimus, or sirolimus/probucol); DP-DES anti-proliferative drug (everolimus, paclitaxel, sirolimus, or zotarolimus); generation of DP-DES (first-generation or second-generation); and duration of DAPT (6 months or 12 months). Statistical analysis was conducted using RevMan Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen).

3. Results {#sec3}
==========

3.1. Study selection {#sec3.1}
--------------------

[Fig. 1](#fig1){ref-type="fig"} shows the study selection process. A total of 1218 references were identified through electronic database searches. After duplicate references were removed, we retrieved 1026 potentially relevant articles. In the present meta-analysis, we included 13 RCTs \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] consisting of 8021 patients with coronary artery disease who were randomized to receive PCI with either PF-DES (n = 4545) or DP-DES (n = 3476). [Table 1](#tbl1){ref-type="table"} outlines the study characteristics of the included trials. Patients receiving PF-DES were treated with either amphilimus-, biolimus-, paclitaxel-, sirolimus-, or sirolimus/probucol-eluting stent. Patients receiving DP-DES were treated with either everolimus-, paclitaxel-, sirolimus-, or zotarolimus-eluting stent.Fig. 1Study selection process.Fig. 1Table 1Study characteristics.Table 1StudyYearPatient (n)DAPT (months)Follow-Up (months)Anti-Proliferative DrugOutcomesPF-DESDP-DESPF-DESDP-DESBioFreedom FIM \[[@bib19]\]201612260660BiolimusPaclitaxelDefinite or probable ST, MI, cardiac death, all-cause death, TLR, TVRDang \[[@bib20]\]20125055612PaclitaxelSirolimusDefinite or probable ST, MI, cardiac death, all-cause death, TLRISAR-TEST \[[@bib21]\]2013225225660SirolimusPaclitaxelDefinite or probable ST, MI, cardiac death, all-cause death, TLRISAR-TEST-2 \[[@bib16]\]20103333351224Sirolimus/ProbucolSirolimusDefinite or probable ST, MI, all-cause deathISAR-TEST-3 \[[@bib17]\]20092012021224SirolimusSirolimusDefinite or probable ST, MI, all-cause death, TLRISAR-TEST-5 \[[@bib22]\]201620021000660Sirolimus/ProbucolZotarolimusDefinite or probable ST, MI, cardiac death, all-cause death, TLR, TVRLIPSIA Yukon \[[@bib26]\]20141181141260SirolimusPaclitaxelDefinite or probable ST, MI, cardiac death, all-cause death, TLR, TVRNano \[[@bib27]\]20141321361224SirolimusSirolimusDefinite or probable ST, MI, cardiac death, all-cause death, TVRNEXT \[[@bib18]\]2012148148612AmphilimusPaclitaxelDefinite or probable ST, MI, cardiac death, all-cause death, TLR, TVRReCre8 \[[@bib24]\]20187477441212AmphilimusZotarolimusDefinite or probable ST, MI, cardiac death, all-cause death, TLRRESERVOIR \[[@bib23]\]201656561212AmphilimusEverolimusMI, cardiac deathShiratori \[[@bib25]\]20148480624PaclitaxelPaclitaxelDefinite or probable ST, MI, cardiac death, all-cause death, TLR, TVRZhang \[[@bib28]\]20133273211224PaclitaxelSirolimusDefinite or probable ST, MI, cardiac death, all-cause death, TVR[^1]

The Cochrane Collaboration risk of bias tool assessed the RCTs to be of high quality and appropriate for inclusion in the present meta-analysis, with minimal risk of bias ([Supplementary Table 1](#appsec1){ref-type="sec"}) \[[@bib13]\]. All trials had a randomized and multicenter design that defined the patient populations and clinical outcomes, with a median follow-up of 24 months. One trial \[[@bib19]\] included three comparison arms of patients randomized to receive either standard-dose polymer-free biolimus-eluting stents (PF-BES), low-dose PF-BES, or DP-DES. Data for standard- and low-dose PF-BES were pooled together. Two trials \[[@bib17],[@bib28]\] included a third comparison arm of patients randomized to receive BP-DES. Data from these third comparison arms were excluded, since BP-DES were irrelevant to our research question. Earlier reports of two trials \[[@bib22],[@bib26]\] were excluded because the institutions published a more recent report with greater length of follow-up.

3.2. Patient and procedural characteristics {#sec3.2}
-------------------------------------------

[Table 2](#tbl2){ref-type="table"} outlines the baseline characteristics of the included trials. The weighted mean age of enrolled patients receiving PF-DES was 66.3 ± 10.9 years and those receiving DP-DES was 66.3 ± 10.6 years. Overall, the two comparison arms had similar proportions of male patients and with comorbidities, previous procedures, clinical presentations, and target vessel locations (all *P* \> 0.05).Table 2Baseline characteristics.Table 2Baseline CharacteristicPF-DESDP-DESRR or WMD (95% CI)*P* ValueAge (years)66.3 ± 10.966.3 ± 10.6−0.39 (−1.03 to 0.25)0.23Male3403/4572 (74.4)2617/3503 (74.7)0.99 (0.97--1.02)0.49Diabetes mellitus1361/4572 (29.8)1025/3503 (29.3)1.00 (0.97--1.03)0.80Hypertension3002/4572 (65.7)2258/3503 (64.5)1.01 (0.98--1.04)0.49Hyperlipidemia2545/4452 (57.2)1939/3387 (57.2)0.97 (0.93--1.00)0.08Current smoking1028/4432 (23.2)794/3367 (23.6)1.06 (0.98--1.15)0.15Previous MI1120/4572 (24.5)846/3503 (24.2)0.97 (0.89--1.04)0.38Previous PCI338/1807 (18.7)353/1745 (20.2)0.90 (0.79--1.02)0.10Previous CABG352/4095 (8.6)258/3079 (8.4)1.00 (0.85--1.17)0.98Clinical presentation Stable angina1691/3254 (52.0)1001/2181 (45.9)1.04 (0.97--1.11)0.26 Unstable angina1125/3767 (29.9)861/2700 (31.9)0.95 (0.89--1.01)0.09Target vessel location Left anterior descending2444/5177 (47.2)1809/3672 (31.9)0.96 (0.91--1.02)0.24 Left circumflex1373/5177 (26.5)983/3672 (26.8)1.04 (0.94--1.14)0.43 Right coronary1691/5177 (32.7)1195/3672 (32.5)1.03 (0.97--1.09)0.35[^2]

3.3. Definite or probable stent thrombosis {#sec3.3}
------------------------------------------

Twelve trials \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22],[@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] reported definite or probable stent thrombosis (ST) in 7909 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of definite or probable ST (1.2% vs 1.2%; RR, 0.94; 95% CI, 0.62--1.43; *P* = 0.77; I^2^ = 0%; [Fig. 2](#fig2){ref-type="fig"}).Fig. 2Risk of definite or probable stent thrombosis. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 2

3.4. Myocardial infarction {#sec3.4}
--------------------------

Thirteen trials \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] reported myocardial infarction (MI) in 8021 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of MI (4.0% vs 3.6%; RR, 1.06; 95% CI, 0.85--1.33; *P* = 0.61; I^2^ = 0%; [Fig. 3](#fig3){ref-type="fig"}).Fig. 3Risk of myocardial infarction. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 3

3.5. Cardiac death {#sec3.5}
------------------

Eleven trials \[[@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] reported cardiac death in 6950 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of cardiac death (5.6% vs 4.6%; RR, 0.98; 95% CI, 0.80--1.21; *P* = 0.88; I^2^ = 0%; [Fig. 4](#fig4){ref-type="fig"}).Fig. 4Risk of cardiac death. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 4

3.6. All-cause death {#sec3.6}
--------------------

Twelve trials \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22],[@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] reported all-cause death in 7909 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of all-cause death (9.6% vs 8.8%; RR, 0.87; 95% CI, 0.76--1.00; *P* = 0.06; I^2^ = 0%; [Fig. 5](#fig5){ref-type="fig"}).Fig. 5Risk of all-cause death. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 5

3.7. Target lesion revascularization {#sec3.7}
------------------------------------

Nine trials \[[@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22],[@bib24], [@bib25], [@bib26]\] reported target lesion revascularization (TLR) in 6325 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of TLR (11.7% vs 9.8%; RR, 1.12; 95% CI, 0.94--1.33; *P* = 0.22; I^2^ = 10%; [Fig. 6](#fig6){ref-type="fig"}).Fig. 6Risk of target lesion revascularization. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 6

3.8. Target vessel revascularization {#sec3.8}
------------------------------------

Seven trials \[[@bib18],[@bib19],[@bib21],[@bib22],[@bib25],[@bib26],[@bib28]\] reported target vessel revascularization (TVR) in 4792 patients. There was no significant difference between patients receiving PF-DES and those receiving DP-DES for the risk of TVR (17.5% vs 14.5%; RR, 1.18; 95% CI, 0.87--1.61; *P* = 0.29; I^2^ = 46%; [Fig. 7](#fig7){ref-type="fig"}).Fig. 7Risk of target vessel revascularization. DP-DES = durable polymer drug-eluting stents. M-H = Mantel-Haenszel. PF-DES = polymer-free drug-eluting stents.Fig. 7

3.9. Subgroup analyses {#sec3.9}
----------------------

[Table 3](#tbl3){ref-type="table"} outlines the safety and efficacy outcomes in different subgroups. At 1 year, 2 years, and 5 years of follow-up, there were no significant differences between patients with PF-DES and those with DP-DES for the risks of definite or probable ST, MI, cardiac death, all-cause death, TLR, and TVR (all *P* \> 0.05). In addition, our landmark analysis beyond 1 year of follow-up showed no significant differences between patients with PF-DES and those with DP-DES for all outcomes (all *P* \> 0.05). Our subgroup analysis based on PF-DES anti-proliferative drug (amphilimus, biolimus, paclitaxel, sirolimus, or sirolimus/probucol) showed no significant differences between patients with PF-DES and those with DP-DES for the risks of definite or probable ST, MI, cardiac death, all-cause death, and TVR (all *P* \> 0.05). A similar result was observed in the risk of TLR for all PF-DES anti-proliferative drugs except for paclitaxel. Two trials \[[@bib20],[@bib25]\] reported TLR in 134 patients receiving polymer-free paclitaxel-eluting stents (PF-PES) and 135 patients receiving DP-DES. Patients with PF-PES had a significantly increased risk of TLR than those with DP-DES (24.6% vs 10.4%; RR, 2.32; 95% CI, 1.30--4.14; *P* = 0.005; I^2^ = 0%). Our subgroup analyses based on DP-DES anti-proliferative drug (everolimus, paclitaxel, sirolimus, or zotarolimus), generation of DP-DES (first-generation or second-generation) and duration of DAPT (6 months or 12 months) showed no significant differences between patients with PF-DES and those with DP-DES for all outcomes (all *P* \> 0.05).Table 3Safety and efficacy outcomes.Table 3AnalysisDefinite or Probable STMICardiac DeathAll-Cause DeathTLRTVROutcomes at longest follow-up0.94 (0.62--1.43)1.06 (0.85--1.33)0.98 (0.80--1.21)0.87 (0.76--1.00)1.12 (0.94--1.33)1.18 (0.87--1.61)Outcomes at 1 year1.38 (0.56--3.43)1.12 (0.68--1.85)1.08 (0.50--2.32)0.87 (0.48--1.60)1.04 (0.65--1.67)2.00 (0.51--7.85)Outcomes at 2 years0.85 (0.39--1.82)1.06 (0.64--1.73)0.88 (0.36--2.16)0.82 (0.52--1.29)1.81 (0.89--3.68)1.52 (0.75--3.08)Outcomes at 5 years0.91 (0.50--1.69)0.96 (0.70--1.32)1.01 (0.79--1.28)0.90 (0.77--1.06)1.02 (0.85--1.21)1.00 (0.87--1.15)Landmark analysis beyond 1 year0.34 (0.01--8.20)0.44 (0.13--3.50)0.46 (0.24--81.57)0.85 (0.45--1.62)1.09 (0.51--2.33)1.07 (0.43--2.66)Subgroup analysisPF-DES anti-proliferative drug Amphilimus1.42 (0.54--3.73)1.12 (0.67--1.87)1.15 (0.52--2.54)0.90 (0.49--1.67)1.00 (0.60--1.65)2.00 (0.51--7.85) BiolimusNR1.23 (0.25--6.15)5.46 (0.31--97.06)1.48 (0.50--4.38)1.15 (0.46--2.84)1.31 (0.65--2.64) Paclitaxel0.97 (0.35--2.70)1.12 (0.43--2.87)0.81 (0.33--2.00)0.84 (0.37--1.90)\*2.32 (1.30--4.14)1.61 (0.55--4.71) Sirolimus0.67 (0.17--2.60)1.52 (0.92--2.50)0.86 (0.52--1.42)0.84 (0.59--1.21)1.09 (0.81--1.46)0.85 (0.55--1.34) Sirolimus/Probucol0.85 (0.47--1.52)0.90 (0.66--1.22)1.00 (0.78--1.29)0.87 (0.74--1.02)1.02 (0.84--1.23)1.01 (0.87--1.17)DP-DES anti-proliferative drug EverolimusNR0.33 (0.01--8.01)3.00 (0.12--72.10)NRNRNR Paclitaxel0.77 (0.17--3.55)1.43 (0.75--2.72)0.97 (0.54--1.74)0.75 (0.48--1.19)1.29 (0.76--2.20)1.93 (0.23--3.02) Sirolimus0.81 (0.38--1.72)1.03 (0.62--1.71)0.80 (0.31--2.07)0.80 (0.51--1.27)1.30 (0.80--2.14)0.86 (0.32--2.34) Zotarolimus1.01 (0.59--1.72)0.99 (0.74--1.33)1.00 (0.79--1.28)0.88 (0.75--1.03)1.02 (0.85--1.23)1.01 (0.87--1.17)Generation of DP-DES First-generation0.85 (0.44--1.64)1.19 (0.83--1.69)0.91 (0.59--1.39)0.86 (0.65--1.14)1.23 (0.93--1.64)1.29 (0.83--2.02) Second-generation1.01 (0.59--1.72)0.98 (0.73--1.32)1.01 (0.80--1.28)0.88 (0.75--1.03)1.02 (0.85--1.23)1.01 (0.87--1.17)Duration of DAPT 6 months0.85 (0.48--1.53)1.01 (0.75--1.38)0.99 (0.79--1.25)0.86 (0.74--1.00)1.18 (0.87--1.60)1.48 (0.87--2.51) 12 months1.04 (0.57--1.91)1.12 (0.80--1.56)0.94 (0.57--1.56)0.94 (0.69--1.30)1.12 (0.81--1.57)0.86 (0.57--1.29)[^3]

4. Discussion {#sec4}
=============

The present meta-analysis of 13 RCTs compared the safety and efficacy profiles between PF-DES and DP-DES in a total of 8021 patients with coronary artery disease. Our findings demonstrated that the two stent platforms had similar rates of definite or probable ST, MI, cardiac death, all-cause death, TLR, and TVR. Overall, there were no identifiable safety and efficacy advantages of PF-DES over DP-DES. A meta-analysis \[[@bib29]\] of 6178 patients found no significant differences between PF-DES and DP-DES for the risk of definite or probable ST at both short- (≤1 year) (odds ratio \[OR\], 0.95; 95% CI 0.54--1.67; *P* = 0.43) and long-term (\>1 year) follow-up (OR, 0.75; 95% CI, 0.36--1.55; *P* = 0.53). Similar outcomes were observed for the risks of mortality, TLR, and TVR at both short- and long-term follow-up (all *P* \> 0.05).

PF-DES were introduced with the aim to overcome the risks of late safety and efficacy outcomes associated with the preceding generations of devices. The polymer coating used in DP-DES has been shown to cause chronic inflammation and delayed vascular healing \[[@bib30]\]. A meta-analysis \[[@bib31]\] of 6575 patients reported that PF-DES had a significantly reduced risk of all-cause death compared with DP-DES (OR, 0.77; 95% CI, 0.61--0.98; *P* = 0.03). The present meta-analysis showed that the reduced risk of all-cause death associated with PF-DES was attenuated, and no longer reached statistical significance, with minimal heterogeneity between studies. This finding may be attributed to the inclusion of recent RCTs \[[@bib23],[@bib24]\] comparing PF-DES with second-generation DP-DES. The new generation of DP-DES were found to have a significantly reduced risk of all-cause death compared with first-generation DP-DES (RR, 0.58; 95% CI, 0.37--0.90; *P* = 0.01) \[[@bib32]\].

The polymer coating in DP-DES has multiple functions, such as stabilizing and binding the anti-proliferative drug to the stent platform and slowing down the rate of drug elution \[[@bib33]\]. The ongoing challenge in the development of PF-DES has been maintaining these functions, while improving biocompatibility without the polymer coating. In general, PF-DES have a microporous metallic stent platform and an inorganic coating that can be loaded with an anti-proliferative drug \[[@bib8]\]. These modifications in stent design and structure compared to preceding generations of devices will affect the elution profile of different anti-proliferative drugs \[[@bib34]\]. Hence, we performed subgroup analyses based on PF-DES anti-proliferative drug (amphilimus, biolimus, paclitaxel, sirolimus, or sirolimus/probucol) and DP-DES anti-proliferative drug (everolimus, paclitaxel, sirolimus, or zotarolimus), which showed no significant differences between PF-DES and DP-DES for all outcomes except for TLR in PF-PES. Our subgroup analyses found that PF-PES had a significantly increased risk of TLR compared with DP-DES. This finding might not reflect a true difference due to the small sample size from two trials \[[@bib20],[@bib25]\]. Nevertheless, a trial \[[@bib35]\] of 1043 patients with PF-PES showed that approximately 40% of the anti-proliferative drug was lost from the stent surface during delivery of the device. This issue in drug release kinetics causes non-uniform local drug distribution, abnormal neointimal hyperplasia, and in-stent restenosis, which may contribute to the increased risk of TLR associated with PF-PES, as observed in our sensitivity analyses.

Second-generation DP-DES were shown to have improved clinical outcomes compared with first-generation DP-DES \[[@bib6]\]. Our subgroup analysis based on generation of DP-DES found no significant differences for all outcomes. However, this finding should be interpreted with caution due to the small sample size. The comparison of safety and efficacy outcomes between PF-DES and second-generation DP-DES was derived from three trials \[[@bib22], [@bib23], [@bib24]\].

The proposed rationale for developing PF-DES was to improve vascular healing in the stented segment, resulting in a shorter duration of DAPT following stent implantation \[[@bib36]\]. However, our subgroup analysis based on duration of DAPT (6 months or 12 months) found no significant differences between PF-DES and DP-DES for all outcomes. The latest American College of Cardiology and American Heart Association (ACC/AHA) guidelines \[[@bib7]\] have reduced the recommended duration of DAPT from 12 months to 6 months in patients receiving DES. There have been suggestions that short-term (1 month) DAPT may be safe following PF-DES implantation \[[@bib37]\]. The LEADERS FREE trial \[[@bib38]\] of 2466 patients found that PF-DES were superior to BMS with respect to primary safety endpoint (composite of definite or probable ST, MI, and cardiac death; hazards ratio \[HR\], 0.80; 95% CI, 0.64--0.99; *P* \< 0.039) and primary efficacy endpoint (TLR; HR, 0.54; 95% CI, 0.41--0.72; *P* \< 0.0001) when used with 1-month DAPT. The elimination of the polymer coating in PF-DES is thought to reduce the risk of very late ST compared with DP-DES. However, this theoretical benefit was not demonstrated at 1 year, 2 years, and 5 years of follow-up, as well as in our landmark analysis beyond 1 year of follow-up, which showed no significant difference between PF-DES and DP-DES for the risk of definite or probable ST.

In the present meta-analysis, electronic database searches were limited to RCTs to reduce the risk of bias. However, there were several limitations that deserve consideration. Firstly, as with any meta-analysis, our study should be interpreted in light of the limitations in design and quality of the original studies, which often compared stents with various anti-proliferative drugs, durations of DAPT, and lengths of follow-up. To address this source of bias, we performed subgroup analyses based on these variables. A network meta-analysis comparing different types of DES may be considered for future research when further trials become available. Secondly, the original studies did not report outcomes according to baseline characteristics, so we were unable to perform subgroup analyses to determine if these variables might influence the results. Thirdly, the exclusion of data from unpublished RCTs may have reduced the potential number of patients in each comparison arm. Fourthly, some reports of the original studies did not describe the randomization techniques, which made it difficult to assess the risk of bias. Finally, trials with greater length of follow-up in larger number of patients are necessary to evaluate the long-term safety and efficacy profiles of PF-DES compared with DP-DES. Further trials with shortened duration of DAPT are warranted to realize the theoretical benefits of PF-DES.

5. Conclusions {#sec5}
==============

In summary, our findings demonstrated similar safety and efficacy profiles between PF-DES and DP-DES. The two stent platforms had equivalent safety and efficacy outcomes, including comparable rates of definite or probable ST.
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Appendix A. Supplementary data {#appsec1}
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The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.amsu.2018.12.003>.

[^1]: DAPT = dual antiplatelet therapy; DP-DES = durable polymer drug-eluting stents; MI = myocardial infarction; PF-DES = polymer-free drug-eluting stents; ST = stent thrombosis; TLR = target lesion revascularization; TVR = target vessel revascularization.

[^2]: Values are n/N (%) or mean ± SD; DP-DES = durable polymer drug-eluting stents; PF-DES = polymer-free drug-eluting stents; RR, risk ratio; WMD = weighted mean difference.

[^3]: Values are risk ratio (95% confidence interval); MI = myocardial infarction; NR = not reported; PF-DES = polymer-free drug-eluting stents; TLR = target lesion revascularization; TVR = target vessel revascularization; ST = stent thrombosis; \* = statistical significance (*P* \< 0.05).
